Benzophenone

Endpoint summary

Additional information

Key studies: Based on available studies performed with benzophenone where it was determined to be negative (two in-vitro studies on mutation reverse bacterial assay (test method equivalent to 471), a gene mutation in mammalian cells (test method equivalent to OECD 476), and two in-vivo micronucleous studies in bone marrow and peripheral blood), benzophenone is considered to be non-genotoxic.

Supporting studies:

In a study performed according to a new bacterial reversion assay, the WP2 Mutoxitest, which is used for the detection of oxidative mutagenicity in E.coli, the test substance was determined to be negative under the test conditions.

In a SOS/umu test, benzophenone induced umu gene expression after metabolic activation by recombinant human cytochrome P450s. Negative results were obtained in the presence or absence of human, rat or mouse liver microsomes.

In a DNA damage/repair test, the test item did not reveal a positive result since no DNA repair was detected in the DNA polymerase-deficient mutant of E. coli strains.

Benzophenone was negative in the in-vivo flow cytometer-based micronucleus assay in mouse since no increase in the frequencies of micronucleated polychromatic erythrocytes was found in the peripheral blood.

Justification for selection of genetic toxicity endpoint
No study was selected since all the studies were negative.

Short description of key information:
Key study: Equivalent to OECD 471. Test item was negative.
Key study: Equivalent to OECD 471. Test item was negative.
Key study: Equivalent to OECD 476. Test item was negative.
Key study: Equivalent to OECD 474. Test item was negative.
Key study. Equivalent to OECD 474. Test item was negative.

Endpoint Conclusion: No adverse effect observed (negative)